Prescient Therapeutics (ASX: PTX) receives R&D Tax Rebate of $2.4M
In the latest announcement, clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) revealed the receipt...
In the latest announcement, clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) revealed the receipt...
Encouraging outcomes from Prescient Therapeutics’ (ASX: PTX) clinical-stage assets light up last quarter and products...
Pitt Street Research has sent us its thesis on biotech stock, Prescient Therapeutics (ASX:PTX), with a valuation range...
Pitt Street Research has released an equity valuation report on clinical stage oncology company Prescient...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF)'s lead compound PTX-100 is potentially a significant future treatment for...
Cancer remains one of the most pressing public health challenges worldwide, affecting millions of lives...
Prescient Therapeutics is a Melbourne-based drug developer focused on cancer, with several platforms and products...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has had its abstract for PTX-100 published on the American Society...
Prescient Therapeutics (ASX: PTX) reported encouraging results in several key targeted and cell therapies in...
It’s a wrap for the September quarter. Here are some of the latest highlights from...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.